Sun Pharma exec settles insider trading case
The case relates to their trading in shares of Ranbaxy Laboratories in 2014.12-04-2019
12-04-2019
Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments11-04-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Raksha Sudhir Valia10-04-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Update On (A) Transition Of India Domestic Formulations Distribution To Sun Pharma'S Wholly Owned Subsidiary And (B) Completion Of Assignment From Atlas Global Trading To Sun Pharma'S Wholly Owned Subsidiary
We refer to our intimation dated 22nd January, 2019 to stock exchanges stating Sun Pharmaceutical Industry Limited's ('Sun Pharma') intent to (a) transition its distribution related to India domestic formulations business from Aditya Medisales Ltd ('AML'), the current distributor, to a wholly owned subsidiary of Sun Pharma and (b) unwinding of a transaction with Atlas Global Trading ('Atlas'). We wish to update that Sun Pharma Distributors Ltd (SPDL), a wholly-owned subsidiary of Sun Pharma Laboratories Limited has been incorporated and will w.e.f. April-2019, commence distributing Sun Pharma's formulation products in India, on the same terms as was with AML, in a phased manner upon receipt of requisite regulatory approvals. This phased transition is expected to be fully completed by Q1 of FY20. The above-mentioned transition and consequential one-time reduction in sales and profit will impact Sun Pharma's financial results for the period ended 31st March 2019. Further, in continuation of our intimation dated 22nd January, 2019, we wish to update that Atlas has completed assignment of its business rights and obligations including those arising from the supply contract with Sun Pharma to a wholly owned subsidiary of Sun Pharma. This has no material impact on the profit or loss for the year ended March 31, 2019. This is for your information and records.08-04-2019
Sun Pharma launches Infugem injection for treatment of cancer in the US
Sun Pharma said INFUGEM uses its proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in ready-to-infuse final dosage bags08-04-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to launch ornReady-to-Infuse INFUGEM in the U.S., which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,08-04-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
This is to inform you that in compliance with the requirements of revised clause 4 of Schedule B to the SEBI (Prohibition of Insider Trading) Regulations, 20 15 and pursuant to the clarifications issued under BSE Circular No. LIST/COMP/0112019-20 dated 2nd April, 2019 and NSE letter no. NSE/CML/2019/ll dated 2nd April, 2019, the window closure for trading by Designated Persons of the Company shall be with effect from tomorrow i.e. Thursday, 4th April 2019 till 48 hours after the declaration of financial results of the Company tor the quarter and year ended 31st March 2019. The date of Board Meeting of the Company for declaration of the financial results tor the quarter and year ended on 31st March 2019 will be intimated in due course. This is for your information and record.03-04-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditya Medisales Ltd03-04-2019
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations, 2015 As Amended From Time To Time.
In compliance with the requirements of the SEBI (Prohibition of Insider Trading), 2015 as amended from time to time we hereby inform you that pursuant to the requirements of SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 and SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2019, the Company has amended 'Code of Practices & Procedures for Fair Disclosure of Unpublished Price Sensitive Information' which is effective from today, i.e. 1st April, 2019, a copy of which is enclosed herewith for your record. This is for your information and records.01-04-2019
Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments30-03-2019